Back to top
more

Sutro Biopharma (STRO)

(Real Time Quote from BATS)

$3.52 USD

3.52
247,991

-0.20 (-5.38%)

Updated Apr 24, 2024 01:19 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for STRO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Sutro Biopharma, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 376 334 198 368 118
Receivables 36 7 12 6 6
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 10 12 8 4 4
Total Current Assets 422 353 219 378 129
Net Property & Equipment 22 25 23 13 10
Investments & Advances 0 0 69 0 16
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 4 3 3 3 3
Total Assets 471 407 341 394 156
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 9 5 11 6 6
Current Portion Long-Term Debt 4 13 9 0 1
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 53 28 11 9 6
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 21 17 9 15 20
Total Current Liabilities 94 67 42 30 33
Mortgages 0 0 0 0 0
Deferred Taxes/Income 53 90 0 7 17
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 4 16 25 9
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 151 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 321 190 89 62 59
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 709 670 586 560 293
Retained Earnings -559 -453 -333 -228 -196
Other Equity 0 -1 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 150 217 253 332 98
Total Liabilities & Shareholder's Equity 471 407 341 394 156
Total Common Equity 150 217 253 332 98
Shares Outstanding 60.90 57.40 46.20 38.60 23.00
Book Value Per Share 2.46 3.78 5.47 8.60 4.25

Fiscal Year End for Sutro Biopharma, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 376 355 392 276
Receivables NA 36 17 10 10
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 10 9 10 18
Total Current Assets NA 422 381 412 304
Net Property & Equipment NA 22 22 24 24
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 4 4 4 4
Total Assets NA 471 432 465 358
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 9 6 4 5
Current Portion Long-Term Debt NA 4 7 10 13
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 53 31 29 19
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 21 24 18 17
Total Current Liabilities NA 94 74 67 59
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 53 78 80 85
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 143 137 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 321 319 310 173
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 709 703 696 688
Retained Earnings NA -559 -590 -541 -503
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 150 112 155 185
Total Liabilities & Shareholder's Equity NA 471 432 465 358
Total Common Equity 0 150 112 155 185
Shares Outstanding 62.40 60.90 60.90 60.10 60.10
Book Value Per Share 0.00 2.46 1.84 2.57 3.09